ZYMEWORKS INC.
Last · NASDAQ$24.77-0.30 (-1.20%)close · yahoo · 11h ago
Market cap$1.78B71.2M sh
P/E · TTM-12.3fwd 23.4 · eps -2.02 · loss
Beta1.17vs S&P 500
Div yield0.00%annual · TTM
52w range
$16.00$31.34
Volume556.6Ksession
| Revenue | $37.1M |
|---|---|
| Operating income | $-89.3M |
| Net income | $-89.2M |
| Free cash flow | $-77.9M |
| Operating margin | -240.5% |
| Net margin | -240.2% |
| Return on equity | -111.0% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-02
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Sbc Revenue High — SBC/Revenue 26.5%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -76.6%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -31.1%
- Cash Runway Low — Cash runway ~1.2 years
- Accumulated Deficit High — Accumulated deficit / equity 355%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
$2.15
Est. revenue
218.3M
Press & signals
- GlobeNewswire
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
- GlobeNewswire
Zymeworks Completes Acquisition of Theravance Biopharma
- GlobeNewswire
Zymeworks to Acquire Theravance Biopharma, Inc.
Documents
FormReporting forFiledFlags